Outsourcing

Arranta Bio will use Cytiva’s FlexFactory single-use manufacturing platform to produce mRNA vaccines.

Recipharm will build up its biologics service offering with the acquisition of GenIbet.

Experience is an invaluable asset for outsourcing partners, particularly as more challenging method development services are in demand.

Demand for outsourced services of technical R&D activities is increasing.

Recent news surrounding CDMOs provides insight into ongoing trends in the sector.

A key benefit for companies when outsourcing formulation development is the broad experience they can gain from a dedicated service provider, particularly for niche markets.

Industry experts share their top outsourcing tips from both the perspective of companies offering outsourcing services as well as for companies looking to outsource.

Shifting demands from industry innovators is leading to an increased need for flexible and agile outsourcing partners offering broad and integrated models.

CDMOs need to consistently demonstrate agility as demand increases for newly developed therapeutic modalities.

CDMOs offer expertise and capacity for spray drying.

CDMOs offer expertise and customization options for sponsors of orphan drugs.

Pharmaceutical Technology Europe's BioPharma Outsourcing Innovation supplement examines outsourcing development services, spray draying, capacity challenges, and more.

Texcell North America’s new lab facility in Frederick, Md., will expand the CRO’s capabilities in R&D cell culture, viral clearance studies, and viral safety testing.

Samsung Biologics has signed an agreement with Biogen to acquire Biogen’s 50% stake in Samsung Bioepis, a joint venture formed by the two companies, for up to $2.3 billion.

Air France KLM Martinair Cargo and Envirotainer are collaborating on more sustainable air transport of pharmaceuticals

Cyxone has appointed a European CDMO to scale-up and produce the active ingredient of its T20K drug candidate.

After a previously announced merger, Protagen Protein Services, BioAnalytix, and GeneWerk have formed a new CRO under the name ProtaGene.

In this episode of the Drug Solutions podcast, Chris Spivey, editorial director, and Meg Rivers, senior editor, interview experts on up-and-coming 2022 trends in the bio/pharma industry.

Fujifilm Diosynth Biotechnologies' 89,000 square-foot expansion of its BioProcess Innovation Center in Research Triangle Park, N.C., will double its capacity to support process characterization.

The agreeement will add to Merck KGaA’s LNP and mRNA capabilities.

The acquisition of Protein Metrics expands Insightful Science’s R&D solutions to include proteomics.

With this investment into Yapan Bio, Piramal Pharma adds new technologies and capabilities in large molecules, including vaccines and gene therapies, to its global offering.

Particle analysis provides assurances of the quality and performance of the final dosage form in pharmaceutical development.

A new focus on speed to market creates challenges for facility design and construction.

Recent developments in the outsourcing industry include a focus on early development services, biosimilar production, and RNA technology.

FUJIFILM Irvine Scientific’s new manufacturing facility in Tilburg, the Netherlands, is now fully operational.

FUJIFILM Diosynth Biotechnologies plans to invest £400 million (US$528 million) to expand its Billingham, Teeside facility in the United Kingdom.

Lonza has signed a five-year services agreement to provide for the development and manufacturing of biologics and small molecules for portfolio companies owned by Bioqube Ventures.

Leucid Bio will collaborate with Lonza to use Lonza’s Cocoon Platform for clinical and commercial manufacturing of CAR T cells for Leucid’s lead candidate.

Particle analysis is a critical component of pharmaceutical development, providing assurances of the quality and performance of the final dosage form.